Adipotide FTPP is a category of proapoptotic peptides capable of eliminating fat cells in the body. They achieve this by cutting off the blood supply specifically to the adipose tissues and not the vessels supplying blood to the rest of the body. Reports of studies performed in monkeys have demonstrated their ability to cause weight loss, which improves symptoms of insulin resistance and reduces the symptoms of type 2 diabetes.
Adipotide FTPP SPECIFICATIONS
Molecular Formula: C152H252N44O42
Molecular Weight: 2611.41 g/mol
Adipotide FTPP and Cancer
Cancerous tissues are able to grow rapidly and become metastatic due to the abundant network of blood vessels. Suppose prohibitin, which has been found in several cancer types, is targeted. In that case, it may be possible to treat cancer in a more focussed manner and avoid the associated side effects brought about due to damage to surrounding healthy tissues due to chemotherapy.
Adipotide and Glucose Tolerance
Glucose tolerance, a common parameter used to diagnose diabetes, is studied by performing a blood test and confirmed by testing fasting glucose levels. In another method, a specific amount of glucose is consumed by the patient and then blood sugar levels are estimated.
Metabolic syndromes such as diabetes have traditionally been controlled by diet and exercise. Both require immense patience and dedication as the outcomes can take months, if not years, to show significant improvement. Most patients with type 2 diabetes are prescribed metformin or sometimes insulin.
Research with adipotides has demonstrated rapid weight-independent improvement in glucose tolerance. This highlights the observation that a reduction in white fat by adipotide FTPP can simultaneously reduce glucose tolerance irrespective of the patient’s weight. These outcomes help to elucidate the mechanisms responsible for diabetes in the first place and also propose the way for novel treatment options.
Although it is unclear whether adipotide FTPP peptide directly causes fat loss or simply decreases the appetite (an indirect factor) the former is more likely as changes in fat cell density and improved glucose tolerance have been observed even without associated weight loss.
Adipotide And Fat Loss
Phase I clinical trials were held in 2011 to investigate the fat-eliminating potential of adipotide. Research on rhesus monkeys showed the ability of this novel drug to induce apoptosis, specifically in the vessels supplying blood to the white adipose tissues. The result being no blood cells and hence, the ensuing death of these fat cells. The eventual outcomes were rapid weight loss, decreased body mass index, and improved insulin sensitivity. Such changes were attributed in part to the ability of adipotide FTPP to bring about changes in the eating pattern of the monkeys, as the monkeys who demonstrated a positive weight loss also demonstrated a reduced appetite.
Research has shown that adipotide is associated with prohibitin, a membrane protein receptor present in blood vessels of white fat tissues and some cancer cells. Adipotide FTPP testing may be used for identifying a fat-specific target for both therapeutic as well as diagnostic purposes if prohibitin is found to be expressed specifically in the vessels supplying blood to the adipose and cancerous tissues.
Future Adipotide FTPP Research
Anti-angiogenic molecules like adipotites target the blood vessels and are considered a very promising treatment for cancer. Most of the research with adipotides have been focused on their effects on fat loss and diabetes. They have been shown to target specifically the blood vessels of adipose tissues in which they induce apoptosis causing them to die. These peptides have demonstrated minimal side effects in addition to low oral and good subcutaneous bioavailability in mice. However, the dosage cannot be directly extrapolated to humans.